Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15391269 | 0.81 | APLNR (0.38) | CYP2D6PTPRCHDAC3HDAC1HDAC2 | |
| SCHEMBL26924263 | 0.81 | CYP2D6 (0.42) | CYP2D6PTPRCHDAC3HDAC1HDAC2 | |
| SCHEMBL26924266 | 0.81 | CYP2D6 (0.42) | CYP2D6PTPRCHDAC3HDAC1HDAC2 | |
| SCHEMBL23551450 | 0.80 | CYP2D6 (0.38) | CYP2D6PTPRCCTSKCA12CA2 | |
| SCHEMBL5189416 | 0.79 | CYP2D6 (0.40) | CYP2D6PTPRCCTSSCTSKCA12 | |
| SCHEMBL4331287 | 0.79 | PTPRC (0.33) | CYP2D6PTPRCCTSSCTSKCA12 | |
| SCHEMBL783009 | 0.78 | CA2 (0.41) | CYP2D6PTPRCCTSKCA12CA2 | |
| SCHEMBL30485492 | 0.78 | CYP2D6 (0.39) | CYP2D6PTPRCCTSKCA12CA2 | |
| SCHEMBL7277502 | 0.77 | PTPRC (0.33) | CYP2D6PTPRCKDM4ECTSSCTSK | |
| SCHEMBL763067 | 0.77 | CA12 (0.38) | CYP2D6PTPRCCTSSCTSKCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539687-A1 | SUBSTITUTED GLYCINE DERIVATIVES FOR USE AS MEDICAMENTS | Pfizer Limited (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040092498-A1 | Substituted glycine derivatives for use as medicaments | BLAKEMORE DAVID (GB) | 2004-05-13 | — | — | US | disclosed |
| WO-2004016583-A1 | SUBSTITUTED GLYCINE DERIVATIVES FOR USE AS MEDICAMENTS | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016583-A1 | SUBSTITUTED GLYCINE DERIVATIVES FOR USE AS MEDICAMENTS | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092498-A1 | Substituted glycine derivatives for use as medicaments | GLRA1, GRM1, GPR6 | CYP2D6 122/4885PTPRC 1577/4885KDM4E 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.